|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. Ca Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Motzer RJ, Bander NH and Nanus DM:
Renal-cell carcinoma. N Engl J Med. 335:865–875. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Johnsen JA and Hellsten S: Lymphatogenous
spread of renal cell carcinoma: An autopsy study. J Urol.
157:450–453. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fyfe G, Fisher RI, Rosenberg SA, Sznol M,
Parkinson DR and Louie AC: Results of treatment of 255 patients
with metastatic renal cell carcinoma who received high-dose
recombinant interleukin-2 therapy. J Clin Oncol. 13:688–696.
1995.PubMed/NCBI
|
|
5
|
Yang JC, Sherry RM, Steinberg SM, Topalian
SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers-Freezer L, Morton
KE, White DE, et al: Randomized study of high-dose and low-dose
interleukin-2 in patients with metastatic renal cancer. J Clin
Oncol. 21:3127–3132. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
McDermott DF, Regan MM, Clark JI, Flaherty
LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff
MS, et al: Randomized phase III trial of high-dose interleukin-2
versus subcutaneous interleukin-2 and interferon in patients with
metastatic renal cell carcinoma. J Clin Oncol. 23:133–141. 2005.
View Article : Google Scholar
|
|
7
|
Nüsslein-Volhard C and Wieschaus E:
Mutations affecting segment number and polarity in Drosophila.
Nature. 287:795–801. 1980. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ingham PW and McMahon AP: Hedgehog
signaling in animal development: Paradigms and principles. Genes
Dev. 15:3059–3087. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Thayer SP, di Magliano MP, Heiser PW,
Nielsen CM, Roberts DJ, Lauwers GY, Qi YP, Gysin S, Fernández-del
Castillo C, Yajnik V, et al: Hedgehog is an early and late mediator
of pancreatic cancer tumorigenesis. Nature. 425:851–856. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sanchez P, Hernández AM, Stecca B, Kahler
AJ, DeGueme AM, Barrett A, Beyna M, Datta MW and Datta S:
Inhibition of prostate cancer proliferation by interference with
SONIC HEDGEHOG-GLI1 signaling. Proc Natl Acad Sci USA.
101:12561–12566. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Qualtrough D, Buda A, Gaffield W, Williams
AC and Paraskeva C: Hedgehog signalling in colorectal tumour cells:
Induction of apoptosis with cyclopamine treatment. Int J Cancer.
110:831–837. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Han Me, Lee YS, Baek SY, Kim BS, Kim JB
and Oh SO: Hedgehog signaling regulates the survival of gastric
cancer cells by regulating the expression of Bcl-2. Int J Mol Sci.
10:3033–3043. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hegde GV, Peterson KJ, Emanuel K, Mittal
AK, Joshi AD, Dickinson JD, Kollessery GJ, Bociek RG, Bierman P,
Vose JM, et al: Hedgehog-induced survival of B-cell chronic
lymphocytic leukemia cells in a stromal cell microenvironment: a
potential new therapeutic target. Mol Cancer Res. 6:1928–1936.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Von Hoff DD, LoRusso PM, Rudin CM, Reddy
JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, et
al: Inhibition of the hedgehog pathway in advanced basal-cell
carcinoma. N Engl J Med. 361:1164–1172. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
LoRusso PM, Rudin CM, Reddy JC, Tibes R,
Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Chang I, Darbonne WC, et
al: Phase I trial of hedgehog pathway inhibitor vismodegib
(GDC-0449) in patients with refractory, locally advanced or
metastatic solid tumors. Clin Cancer Res. 17:2502–2511. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim DJ, Kim J, Spaunhurst K, Montoya J,
Khodosh R, Chandra K, Fu T, Gilliam A, Molgo M, Beachy PA, et al:
Open-label, exploratory phase II trial of oral itraconazole for the
treatment of basal cell carcinoma. J Clin Oncol. 32:745–751. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dormoy V, Danilin S, Lindner V, Thomas L,
Rothhut S, Coquard C, Helwig JJ, Jacqmin D, Lang H and Massfelder
T: The sonic hedgehog signaling pathway is reactivated in human
renal cell carcinoma and plays orchestral role in tumor growth. Mol
Cancer. 8:1232009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Singh RP, Raina K, Deep G, Chan D and
Agarwal R: Silibinin suppresses growth of human prostate carcinoma
PC-3 orthotopic xenograft via activation of extracellular
signal-regulated kinase 1/2 and inhibition of signal transducers
and activators of transcription signaling. Clin Cancer Res.
15:613–621. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu KJ, Zeng J, Zhu GD, Zhang LL, Zhang D,
Li L, Fan JH, Wang XY and He DL: Silibinin inhibits prostate cancer
invasion, motility and migration by suppressing vimentin and MMP-2
expression. Acta Pharmacol Sin. 30:1162–1168. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu K, Ning Z, Zeng J, Fan J, Zhou J, Zhang
T, Zhang L, Chen Y, Gao Y, Wang B, et al: Silibinin inhibits
β-catenin/ZEB1 signaling and suppresses bladder cancer metastasis
via dual-blocking epithelial-mesenchymal transition and stemness.
Cell Signal. 25:2625–2633. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zeng J, Sun Y, Wu K, Li L, Zhang G, Yang
Z, Wang Z, Zhang D, Xue Y, Chen Y, et al: Chemopreventive and
chemotherapeutic effects of intravesical silibinin against bladder
cancer by acting on mitochondria. Mol Cancer Ther. 10:104–116.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tyagi A, Singh RP, Ramasamy K, Raina K,
Redente EF, Dwyer-Nield LD, Radcliffe RA, Malkinson AM and Agarwal
R: Growth inhibition and regression of lung tumors by silibinin:
Modulation of angiogenesis by macrophage-associated cytokines and
nuclear factor-kappaB and signal transducers and activators of
transcription 3. Cancer Prev Res (Phila). 2:74–83. 2009. View Article : Google Scholar
|
|
23
|
Kaur M, Velmurugan B, Tyagi A, Deep G,
Katiyar S, Agarwal C and Agarwal R: Silibinin suppresses growth and
induces apoptotic death of human colorectal carcinoma LoVo cells in
culture and tumor xenograft. Mol Cancer Ther. 8:2366–2374. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Singh RP, Gu M and Agarwal R: Silibinin
inhibits colorectal cancer growth by inhibiting tumor cell
proliferation and angio-genesis. Cancer Res. 68:2043–2050. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li L, Zeng J, Gao Y and He D: Targeting
silibinin in the anti-proliferative pathway. Expert Opin Investig
Drugs. 19:243–255. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cheung CW, Taylor PJ, Kirkpatrick CM,
Vesey DA, Gobe GC, Winterford C, Nicol DL and Johnson DW:
Therapeutic value of orally administered silibinin in renal cell
carcinoma: Manipulation of insulin-like growth factor binding
protein-3 levels. BJU Int. 100:438–444. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li L, Gao Y, Zhang L, Zeng J, He D and Sun
Y: Silibinin inhibits cell growth and induces apoptosis by caspase
activation, down-regulating survivin and blocking EGFR-ERK
activation in renal cell carcinoma. Cancer Lett. 272:61–69. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liang L, Li L, Zeng J, Gao Y, Chen YL,
Wang ZQ, Wang XY, Chang LS and He D: Inhibitory effect of silibinin
on EGFR signal-induced renal cell carcinoma progression via
suppression of the EGFR/MMP-9 signaling pathway. Oncol Rep.
28:999–1005. 2012.PubMed/NCBI
|
|
29
|
Li F, Ma Z, Guan Z, Chen Y, Wu K, Guo P,
Wang X, He D and Zeng J: autophagy induction by silibinin
positively contributes to its anti-metastatic capacity via
AMPK/mTOR pathway in renal cell carcinoma. Int J Mol Sci.
16:8415–8429. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Green DR, Galluzzi L and Kroemer G: Cell
biology. Metabolic control of cell death Science.
345:12502562014.
|
|
31
|
Green DR and Levine B: To be or not to be?
How selective autophagy and cell death govern cell fate. Cell.
157:65–75. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Navarro-Yepes J, Burns M, Anandhan A,
Khalimonchuk O, del Razo LM, Quintanilla-Vega B, Pappa A,
Panayiotidis MI and Franco R: Oxidative stress, redox signaling,
and autophagy: Cell death versus survival. Antioxid Redox Signal.
21:66–85. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fan S, Li L, Chen S, Yu Y, Qi M, Tashiro
S, Onodera S and Ikejima T: Silibinin induced-autophagic and
apoptotic death is associated with an increase in reactive oxygen
and nitrogen species in HeLa cells. Free Radic Res. 45:1307–1324.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zheng N, Zhang P, Huang H, Liu W, Hayashi
T, Zang L, Zhang Y, Liu L, Xia M, Tashiro SI, Onodera S and Ikejima
T: ERalpha down-regulation plays a key role in silibinin-induced
autophagy and apoptosis in human breast cancer MCF-7 cells. J
Pharmacol Sci. May 12–2015.epub ahead of print. View Article : Google Scholar
|
|
35
|
Kauntz H, Bousserouel S, Gossé F and Raul
F: Silibinin triggers apoptotic signaling pathways and autophagic
survival response in human colon adenocarcinoma cells and their
derived metastatic cells. Apoptosis. 16:1042–1053. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Desch P, Asslaber D, Kern D, Schnidar H,
Mangelberger D, Alinger B, Stoecher M, Hofbauer SW, Neureiter D,
Tinhofer I, et al: Inhibition of GLI, but not Smoothened, induces
apoptosis in chronic lymphocytic leukemia cells. Oncogene.
29:4885–4895. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Stecca B, Mas C, Clement V, Zbinden M,
Correa R, Piguet V and Beermann F: Melanomas require HEDGEHOG-GLI
signaling regulated by interactions between GLI1 and the
RAS-MEK/AKT pathways. Proc Natl Acad Sci USA. 104:5895–5900. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Seto M, Ohta M, Asaoka Y, Ikenoue T, Tada
M, Miyabayashi K, Mohri D, Tanaka Y, Ijichi H, Tateishi K, et al:
Regulation of the hedgehog signaling by the mitogen-activated
protein kinase cascade in gastric cancer. Mol Carcinog. 48:703–712.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Nolan-Stevaux O, Lau J, Truitt ML, Chu GC,
Hebrok M, Fernández-Zapico Me and Hanahan D: GLI1 is regulated
through Smoothened-independent mechanisms in neoplastic pancreatic
ducts and mediates PDAC cell survival and transformation. Genes
Dev. 23:24–36. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang Y, Ding Q, Yen CJ, Xia W, Izzo JG,
Lang JY, Li CW, Hsu JL, Miller SA, Wang X, et al: The crosstalk of
mTOR/S6K1 and Hedgehog pathways. Cancer Cell. 21:374–387. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Robb VA, Karbowniczek M, Klein-Szanto AJ
and Henske EP: activation of the mTOR signaling pathway in renal
clear cell carcinoma. J Urol. 177:346–352. 2007. View Article : Google Scholar
|
|
42
|
Pantuck AJ, Seligson DB, Klatte T, Yu H,
Leppert JT, Moore L, O'Toole T, Gibbons J, Belldegrun AS and Figlin
RA: Prognostic relevance of the mTOR pathway in renal cell
carcinoma: implications for molecular patient selection for
targeted therapy. Cancer. 109:2257–2267. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
García-Maceira P and Mateo J: Silibinin
inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1
signalling pathway in human cervical and hepatoma cancer cells:
Implications for anticancer therapy. Oncogene. 28:313–324. 2009.
View Article : Google Scholar
|
|
44
|
Wang JY, Chang CC, Chiang CC, Chen WM and
Hung SC: Silibinin suppresses the maintenance of colorectal cancer
stem-like cells by inhibiting PP2A/AKT/mTOR pathways. J Cell
Biochem. 113:1733–1743. 2012.PubMed/NCBI
|
